RCUS Q4 2019 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+524.2% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$18M-179.8% margin

Net Income

-$17M-170.2% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+457.1%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$203M

Total Liabilities

$39M

Stockholders' Equity

$164M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$2M	+524.2%
Gross Profit	$10M	$2M	+524.2%
Operating Income	-$18M	-$13M	-30.0%
Net Income	-$17M	-$12M	-35.0%